Whole inactivated dengue virus-loaded trimethyl chitosan nanoparticle-based vaccine: immunogenic properties in ex vivo and in vivo models

References

• Huang YJ, Higgs S, Horne KM, Vanlandingham DL. Flavivirus-mosquito interactions. Viruses. 2014;6:4703–30. doi:10.3390/v6114703.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496:504–07. doi:10.1038/nature12060.
   PubMed Web of Science ®Google Scholar
• Rajapakse S. Dengue shock. J Emerg Trauma Shock. 2011;4:120–27. doi:10.4103/0974-2700.76835.
   PubMedGoogle Scholar
• Rather IA, Parray HA, Lone JB, Paek WK, Lim J, Bajpai VK, Park YH. Prevention and control strategies to counter dengue virus infection. Front Cell Infect Microbiol. 2017;7:336. doi:10.3389/fcimb.2017.00336.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Bouckenooghe A. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Expert Rev Vaccines. 2016;15:795–98. doi:10.1080/14760584.2016.1189331.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195–206. doi:10.1056/NEJMoa1506223.
   PubMed Web of Science ®Google Scholar
• Arredondo-Garcia JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, Tran NH, Deseda CC, Wirawan DN, Cortes Supelano M, et al. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. 2018;24:755–63. doi:10.1016/j.cmi.2018.01.018.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine. 2017;35:6355–58. doi:10.1016/j.vaccine.2017.09.089.
   PubMed Web of Science ®Google Scholar
• Flasche S, Wilder-Smith A, Hombach J, Smith PG. Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. Wellcome Open Res. 2019;4:165. doi:10.12688/wellcomeopenres.15507.1.
   PubMedGoogle Scholar
• Handel A, Li Y, McKay B, Pawelek KA, Zarnitsyna V, Antia R. Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. PLoS Comput Biol. 2018;14:e1006505. doi:10.1371/journal.pcbi.1006505.
   PubMed Web of Science ®Google Scholar
• de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012;109:7439–44. doi:10.1073/pnas.1200566109.
   PubMed Web of Science ®Google Scholar
• Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE Jr, Wang WK. Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy for dengue vaccine. J Virol. 2018;92:e00056–18. doi:10.1128/jvi.00556-18.
   Web of Science ®Google Scholar
• Gallichotte EN, Baric TJ, Yount BL Jr, Widman DG, Durbin A, Whitehead S, Baric RS, de Silva AM. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog. 2018;14:e1006934. doi:10.1371/journal.ppat.1006934.
   PubMed Web of Science ®Google Scholar
• Delrue I, Verzele D, Madder A, Nauwynck HJ. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines. 2012;11:695–719. doi:10.1586/erv.12.38.
   PubMed Web of Science ®Google Scholar
• Sundaram AK, Ewing D, Blevins M, Liang Z, Sink S, Lassan J, Raviprakash K, Defang G, Williams M, Porter KR, et al. Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates. Vaccine. 2020;38:3313–20. doi:10.1016/j.vaccine.2020.03.008.
   PubMed Web of Science ®Google Scholar
• Hunsawong T, Sunintaboon P, Warit S, Thaisomboonsuk B, Jarman RG, Yoon IK, Ubol S, Fernandez S. Immunogenic properties of a BCG adjuvanted chitosan nanoparticle-based dengue vaccine in human dendritic cells. PLoS Negl Trop Dis. 2015;9:e0003958. doi:10.1371/journal.pntd.0003958.
   PubMed Web of Science ®Google Scholar
• Yam-Puc JC, Cedillo-Barron L, Aguilar-Medina EM, Ramos-Payan R, Escobar-Gutierrez A, Flores-Romo L. The cellular bases of antibody responses during dengue virus infection. Front Immunol. 2016;7:218. doi:10.3389/fimmu.2016.00218.
   PubMed Web of Science ®Google Scholar
• Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13. doi:10.3389/fcimb.2013.00013.
   PubMed Web of Science ®Google Scholar
• Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224. doi:10.3389/fimmu.2018.02224.
   PubMed Web of Science ®Google Scholar
• Lim M, Badruddoza AZM, Firdous J, Azad M, Mannan A, Al-Hilal TA, Cho CS, Islam MA. Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics. 2020;12:30. doi:10.3390/pharmaceutics12010030.
   PubMed Web of Science ®Google Scholar
• Jearanaiwitayakul T, Sunintaboon P, Chawengkittikul R, Limthongkul J, Midoeng P, Warit S, Ubol S. Nanodelivery system enhances the immunogenicity of dengue-2 nonstructural protein 1, DENV-2 NS1. Vaccine. 2020;38:6814–25. doi:10.1016/j.vaccine.2020.08.021.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015;212:702–10. doi:10.1093/infdis/jiv082.
   PubMed Web of Science ®Google Scholar
• Wang R, Zheng X, Sun J, Feng K, Gao N, Fan D, Chen H, Jin X, An J. Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice. Front Microbiol. 2019;10:1113. doi:10.3389/fmicb.2019.01113.
   PubMed Web of Science ®Google Scholar
• Hunsawong T, Sunintaboon P, Warit S, Thaisomboonsuk B, Jarman RG, Yoon IK, Ubol S, Fernandez S. A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice. Vaccine. 2015;33:1702–10. doi:10.1016/j.vaccine.2015.02.016.
   PubMed Web of Science ®Google Scholar
• Gil-Jaramillo N, Motta FN, Favali CB, Bastos IM, Santana JM. Dendritic cells: a double-edged sword in immune responses during chagas disease. Front Microbiol. 2016;7:1076. doi:10.3389/fmicb.2016.01076.
   PubMed Web of Science ®Google Scholar
• Conde JN, Silva EM, Barbosa AS, Mohana-Borges R. The complement system in flavivirus infections. Front Microbiol. 2017;8:213. doi:10.3389/fmicb.2017.00213.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines. 2016;15:497–508. doi:10.1586/14760584.2016.1128328.
   PubMed Web of Science ®Google Scholar
• Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? Expert Rev Vaccines. 2016;15:509–17. doi:10.1586/14760584.2016.1115727.
   PubMed Web of Science ®Google Scholar
• Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, et al. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg. 2015;92:698–708. doi:10.4269/ajtmh.14-0268.
   PubMed Web of Science ®Google Scholar
• Schmidt AC, Lin L, Martinez LJ, Ruck RC, Eckels KH, Collard A, De La Barrera R, Paolino KM, Toussaint JF, Lepine E, et al. Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States. Am J Trop Med Hyg. 2017;96:1325–37. doi:10.4269/ajtmh.16-0634.
   PubMed Web of Science ®Google Scholar
• Nantachit N, Sunintaboon P, Ubol S. EDIII-DENV3 nanospheres drive immature dendritic cells into a mature phenotype in an in vitro model. Microbiol Immunol. 2017;61:305–17. doi:10.1111/1348-0421.12497.
   PubMed Web of Science ®Google Scholar
• Rungrojcharoenkit K, Sunintaboon P, Ellison D, Macareo L, Midoeng P, Chaisuwirat P, Fernandez S, Ubol S. Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study. PLoS One. 2020;15:e0237218. doi:10.1371/journal.pone.0237218.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu W, Peng Y, Han B, Yang Y. Toll like receptor 4 (TLR4) mediates the stimulating activities of chitosan oligosaccharide on macrophages. Int Immunopharmacol. 2014;23:254–61. doi:10.1016/j.intimp.2014.09.007.
   PubMed Web of Science ®Google Scholar
• Carroll EC, Jin L, Mori A, Munoz-Wolf N, Oleszycka E, Moran HBT, Mansouri S, McEntee CP, Lambe E, Agger EM, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity. 2016;44:597–608. doi:10.1016/j.immuni.2016.02.004.
   PubMed Web of Science ®Google Scholar
• Smeltz RB, Chen J, Ehrhardt R, Shevach EM. Role of IFN-gamma in Th1 differentiation: IFN-gamma regulates IL-18R alpha expression by preventing the negative effects of IL-4 and by inducing/maintaining IL-12 receptor beta 2 expression. J Immunol. 2002;168:6165–72. doi:10.4049/jimmunol.168.12.6165.
   PubMed Web of Science ®Google Scholar
• Yu S, Jia L, Zhang Y, Zhong J, Yang B, Wu C. IL-12 induced the generation of IL-21- and IFN-gamma-co-expressing poly-functional CD4+ T cells from human naive CD4+ T cells. Cell Cycle. 2015;14:3362–72. doi:10.1080/15384101.2015.1093703.
   PubMed Web of Science ®Google Scholar
• Cox MA, Harrington LE, Zajac AJ. Cytokines and the inception of CD8 T cell responses. Trends Immunol. 2011;32:180–86. doi:10.1016/j.it.2011.01.004.
   PubMed Web of Science ®Google Scholar
• Walker JA, McKenzie ANJ. TH2 cell development and function. Nat Rev Immunol. 2018;18:121–33. doi:10.1038/nri.2017.118.
   PubMed Web of Science ®Google Scholar
• Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, Briso EM, Charland C, Leonard WJ, Ciliberto G, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med. 2009;206:69–78. doi:10.1084/jem.20081571.
   PubMed Web of Science ®Google Scholar
• Abkar M, Fasihi-Ramandi M, Kooshki H, Sahebghadam Lotfi A. Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against Brucella melitensis infection. Int J Nanomedicine. 2017;12:8769–78. doi:10.2147/ijn.S149774.
   PubMed Web of Science ®Google Scholar
• Najminejad H, Kalantar SM, Mokarram AR, Dabaghian M, Abdollahpour-Alitappeh M, Ebrahimi SM, Tebianian M, Fasihi Ramandi M, Sheikhha MH. Bordetella pertussis antigens encapsulated into N-trimethyl chitosan nanoparticulate systems as a novel intranasal pertussis vaccine. Artif Cells Nanomed Biotechnol. 2019;47:2605–11. doi:10.1080/21691401.2019.1629948.
   PubMed Web of Science ®Google Scholar
• Mosafer J, Sabbaghi AH, Badiee A, Dehghan S, Tafaghodi M. Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization. Asian J Pharm Sci. 2019;14:216–21. doi:10.1016/j.ajps.2018.04.005.
   PubMed Web of Science ®Google Scholar
• Tsai MH, Chuang CC, Chen CC, Yen HJ, Cheng KM, Chen XA, Shyu HF, Lee CY, Young JJ, Kau JH. Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: in vitro and in vivo efficacy in comparison to CpG. Carbohydr Polym. 2020;236:116041. doi:10.1016/j.carbpol.2020.116041.
   PubMed Web of Science ®Google Scholar
• Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108:717–25. doi:10.1016/s0092-8674(02)00660-8.
   PubMed Web of Science ®Google Scholar
• Kiermayr S, Stiasny K, Heinz FX. Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J Virol. 2009;83:8482–91. doi:10.1128/jvi.00660-09.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6:6341. doi:10.1038/ncomms7341.
   PubMed Web of Science ®Google Scholar
• Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, Pierson TC, Diamond MS. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe. 2007;2:417–26. doi:10.1016/j.chom.2007.09.015.
   PubMed Web of Science ®Google Scholar
• Mehlhop E, Whitby K, Oliphant T, Marri A, Engle M, Diamond MS. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol. 2005;79:7466–77. doi:10.1128/jvi.79.12.7466-7477.2005.
   PubMed Web of Science ®Google Scholar
• Friberg H, Martinez LJ, Lin L, Blaylock JM, De La Barrera RA, Rothman AL, Putnak JR, Eckels KH, Thomas SJ, Jarman RG, et al. Cell-mediated immunity generated in response to a purified inactivated vaccine for dengue virus type 1. mSphere. 2020;5:e00671–19. doi:10.1128/mSphere.00671-19.
   PubMed Web of Science ®Google Scholar
• Smith SA, Selby LI, Johnston APR, Such GK. The endosomal escape of nanoparticles: toward more efficient cellular delivery. Bioconjug Chem. 2019;30:263–72. doi:10.1021/acs.bioconjchem.8b00732.
   PubMed Web of Science ®Google Scholar